MedPath

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures

Phase 2
Recruiting
Conditions
Generalized Epilepsy
Interventions
Drug: Placebo
Registration Number
NCT06425159
Lead Sponsor
Biohaven Therapeutics Ltd.
Brief Summary

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
242
Inclusion Criteria
  • Male and Female participants 18 to 75 years of age at time of consent.

  • Diagnosis of Idiopathic Generalized Epilepsy at least 6 months prior to the screening visit, defined by 2017 International League Against Epilepsy (ILAE) Classification and based on requirements of Epilepsy Adjudication criteria.

    1. Subject has probable GTC seizures in the setting of IGE, meaning GTC seizures and either classic 3-4 Hz generalized spike-wave (GSW) or 4-6 Hz polyspike-wave on EEG and no focal abnormality (asymmetric spike-wave fragment is allowed) AND/OR a clear history of absence seizures or myoclonic jerks
    2. Subjects with possible GTC seizures in the setting of IGE, meaning GTC and either Normal EEG OR Generalized epileptiform EEG abnormality with atypical spike-wave and no focal abnormality (asymmetric spike-wave fragment is allowed).
  • Subject meets the 2009 ILAE definition of drug resistant epilepsy, failure of adequate trials of two tolerated and appropriately chosen and used ASM schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.

  • Ability of subject or caregiver to keep accurate seizure diaries

  • Current treatment with at least 1 to 3 ASMs as part of no more than 4 epilepsy treatments in total (e.g., each ASM is considered 1 treatment. Other epilepsy therapies including devices and diet therapy are allowed; together these other therapies count as 1 treatment).

  • Accurate history of having at least 3 days with a GTC seizure evenly spread throughout the 16 weeks prior to the screening visit, such that a subject had at least 1 day with a GTC seizure during the first 8 weeks and at least 1 day with a GTC seizure during the second 8 weeks.

Exclusion Criteria
  • History of status epilepticus (convulsive status epilepticus for > 5 minutes or focal status epilepticus with impaired conscious for > 10 minutes) within the last 6 months prior to screening visit that is not consistent with the subject's habitual seizure.
  • History of repetitive/cluster GTC seizures (where individual seizures cannot be counted) within the last 6 months prior to screening visit, or having repetitive/cluster GTC seizures count during the screening phase.
  • Any condition that would interfere with and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
BHV-7000 75 mgBHV-7000-
Primary Outcome Measures
NameTimeMethod
Time to the Second Day with a Generalized Tonic Clonic (GTC) Seizure During the 24- week Double-blind Treatment PeriodBaseline to Week 24 of Double-Blind Treatment Period

To compare the efficacy of BHV-7000 to placebo as adjunctive therapy for subjects with idiopathic generalized epilepsy with generalized tonic-clonic (GTC) seizures as measured by the time to the second day with a GTC seizure during the double-blind phase

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants with freedom of GTC seizures during DBT PhaseBaseline to Week 24 of Double-Blind Treatment Period

To compare the efficacy of BHV-7000 to placebo in terms of the proportion of subjects that are free of GTC seizures as measured by the proportion of subjects with GTC seizure freedom during the 24-week DBP, estimated using Kaplan- Meier methods.

Number of Participants With Clinically Significant Laboratory AbnormalitiesBaseline to Week 24 of Double-Blind Treatment Period

To assess the safety and tolerability of BHV-7000 as measured by the number of unique subjects with grade 3 and grade 4 laboratory abnormalities.

Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEsBaseline to Week 24 of Double-Blind Treatment Period

To assess the safety and tolerability of BHV-7000 as measured by the number of unique subjects with deaths, SAEs, AEs leading to discontinuation, and moderate and severe AEs

Trial Locations

Locations (105)

Hôpital Pontchaillou

🇫🇷

Rennes, France

Accel Research

🇺🇸

Birmingham, Alabama, United States

Barrow Neurological Institute

🇺🇸

Phoenix, Arizona, United States

ARENSIA Exploratory Medicine

🇺🇸

Phoenix, Arizona, United States

Center for Neurosciences

🇺🇸

Tucson, Arizona, United States

WRN

🇺🇸

Rogers, Arkansas, United States

Amicis Research Center

🇺🇸

Lancaster, California, United States

Profound Research LLC

🇺🇸

Pasadena, California, United States

Medstar Health Research Institute

🇺🇸

Washington, District of Columbia, United States

Nova Clinical Research, LLC

🇺🇸

Bradenton, Florida, United States

University of Florida (Jacksonville)

🇺🇸

Jacksonville, Florida, United States

Santa Familia PTG Lodz

🇵🇱

Lódz, Lódzkie, Poland

Y&L Advance Health Care,Inc d/b/a Elite Clinical Research

🇺🇸

Miami, Florida, United States

Serenity Research Center

🇺🇸

Miami, Florida, United States

Floridian Research Institute

🇺🇸

Miami, Florida, United States

Research Institute of Orlando

🇺🇸

Orlando, Florida, United States

Comprehensive Neurology Clinic

🇺🇸

Orlando, Florida, United States

Knight Neurology

🇺🇸

Rockledge, Florida, United States

Santos Research Center

🇺🇸

Tampa, Florida, United States

Encore Medical Research of Weston LLC.

🇺🇸

Weston, Florida, United States

Hawaii Pacific Neuroscience

🇺🇸

Honolulu, Hawaii, United States

Consultants in Epilepsy & Neurology, PLLC (CEN)

🇺🇸

Boise, Idaho, United States

Northwestern Medical Group, Department of Neurology

🇺🇸

Chicago, Illinois, United States

Revive Research Institute, Inc.

🇺🇸

Rochester Hills, Michigan, United States

Bluegrass Epilepsy Research

🇺🇸

Lexington, Kentucky, United States

OLOLRMC

🇺🇸

Baton Rouge, Louisiana, United States

University Medical Center New Orleans

🇺🇸

New Orleans, Louisiana, United States

Boston Clinical Trials

🇺🇸

Boston, Massachusetts, United States

Somnos Clinical Research

🇺🇸

Lincoln, Nebraska, United States

NEREG

🇺🇸

Hackensack, New Jersey, United States

Institute of Neurology and Neurosurgery

🇺🇸

Livingston, New Jersey, United States

Dent Neurosciences Research Center

🇺🇸

Amherst, New York, United States

Montefiore Medical Center

🇺🇸

Bronx, New York, United States

Boston Children's Health Physicians (BCHP)

🇺🇸

Hawthorne, New York, United States

Northwell Health Pediatric Neurology

🇺🇸

New Hyde Park, New York, United States

NYU Langone Health

🇺🇸

New York, New York, United States

OnSite Clinical Solutions

🇺🇸

Charlotte, North Carolina, United States

UPMC

🇺🇸

Pittsburgh, Pennsylvania, United States

WR-ClinSearch

🇺🇸

Chattanooga, Tennessee, United States

Vanderbilt University Medical Center

🇺🇸

Nashville, Tennessee, United States

Clinical Research Solution LLC

🇺🇸

Cypress, Texas, United States

Neurology Consultants of Dallas, PA

🇺🇸

Dallas, Texas, United States

ANESC Research

🇺🇸

El Paso, Texas, United States

Road Runner Research, Ltd

🇺🇸

San Antonio, Texas, United States

Intermountain Health

🇺🇸

Murray, Utah, United States

Henrico Doctors' Neurology Associates, LLC

🇺🇸

Richmond, Virginia, United States

Westmead Hospital

🇦🇺

Westmead, New South Wales, Australia

Royal Brisbane & Women's Hospital

🇦🇺

Herston, Queensland, Australia

St Vincents Hospital Melbourne - PPDS

🇦🇺

Fitzroy, Victoria, Australia

Austin Hospital

🇦🇺

Heidelberg, Victoria, Australia

The Alfred Hospital

🇦🇺

Melbourne, Victoria, Australia

Royal Melbourne Hospital

🇦🇺

Parkville, Victoria, Australia

Christian Doppler-Klinik - Universitätsklinikum der PMU

🇦🇹

Salzburg, Austria

Medizinische Universität Wien

🇦🇹

Wien, Austria

CHU UCL Namur - Site Godinne

🇧🇪

Yvoir, Namur, Belgium

UZ Gent

🇧🇪

Gent, Oost-Vlaanderen, Belgium

Clinical Hospital Dubrava

🇭🇷

Zagreb, Grad Zagreb, Croatia

Clinical Hospital Sveti Duh

🇭🇷

Zagreb, Grad Zagreb, Croatia

Helsinki University Hospital

🇫🇮

Helsinki, Uusimaa, Finland

CHU de Strasbourg - Hôpital de Hautepierre

🇫🇷

Strasbourg, Bas-Rhin, France

CHU Dijon Bourgogne

🇫🇷

Dijon, Côte-d'Or, France

CHU de Toulouse-Hôpital Pierre-Paul Riquet-Site de Purpan

🇫🇷

Toulouse, Haute-Garonne, France

CHRU Lille

🇫🇷

Lille Cedex, Nord, France

Hospices Civils de Lyon - 59 Bd Pinel

🇫🇷

Bron, Rhône, France

Epilepsiezentrum Kork

🇩🇪

Kehl, Baden-Württemberg, Germany

Universitätsklinikum Ulm-Oberer Eselsberg 45

🇩🇪

Ulm, Baden-Württemberg, Germany

Universitätsklinikum Erlangen

🇩🇪

Erlangen, Bayern, Germany

LMU Klinikum der Universität München - Campus Großhadern

🇩🇪

München, Bayern, Germany

Klinikum der Johann-Wolfgang Goethe-Universitat - Schleusenweg 2-16

🇩🇪

Frankfurt am Main, Hessen, Germany

Krankenhaus Mara gGmbH

🇩🇪

Bielefeld, Nordrhein-Westfalen, Germany

Universitätsklinikum Bonn

🇩🇪

Bonn, Nordrhein-Westfalen, Germany

Kleinwachau Sächsisches Epilepsiezentrum Radeberg Gemeinnützige Gmbh

🇩🇪

Radeberg, Sachsen, Germany

Vivantes - Humboldt Klinikum

🇩🇪

Berlin, Germany

Epilepsie-Zentrum Bodensee

🇩🇪

Ravensburg, Germany

Ospedale Policlinico SS Annunziata - Chieti

🇮🇹

Chieti, Abruzzo, Italy

Azienda Ospedaliera Universitaria Renato Dulbecco - AO Mater Domini

🇮🇹

Catanzaro, Calabria, Italy

AORN Antonio Cardarelli

🇮🇹

Napoli, Campania, Italy

AUSL di Bologna - Ospedale Bellaria

🇮🇹

Bologna, Emilia-Romagna, Italy

IRCCS Istituto Neurologico Mediterraneo Neuromed

🇮🇹

Pozzilli, Isernia, Italy

Fondazione PTV Policlinico Tor Vergata

🇮🇹

Roma, Lazio, Italy

IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN

🇮🇹

Roma, Lazio, Italy

Istituto G Gaslini Ospedale Pediatrico IRCCS - INCIPIT - PIN

🇮🇹

Genova, Liguria, Italy

Ospedale San Raffaele S.r.l. - PPDS

🇮🇹

Milano, Lombardia, Italy

ASST Santi Paolo e Carlo - Azienda Universitaria-Polo Universitario San Paolo

🇮🇹

Milano, Lombardia, Italy

Fondazione Istituto Neurologico Nazionale Casimiro Mondino IRCCS

🇮🇹

Pavia, Lombardia, Italy

Fondazione Policlinico Universitario A Gemelli - Rome - PPDS

🇮🇹

Roma, Italy

Azienda Ospedaliera Universitaria Integrata Di Verona

🇮🇹

Verona, Italy

Kempenhaeghe - PPDS

🇳🇱

Heeze, Noord-Brabant, Netherlands

Twoja Przychodnia-Centrum Medyczne Nowa Sol

🇵🇱

Nowa Sol, Lubuskie, Poland

Pratia MCM KrakÛw

🇵🇱

Kraków, Malopolskie, Poland

Centrum Badan Klinicznych PI-House sp. z o.o.

🇵🇱

Gdańsk, Pomorskie, Poland

AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Poznaniu

🇵🇱

Poznań, Wielkopolskie, Poland

Neurosphera SP. Z O.O Warsaw

🇵🇱

Warszawa, Poland

ULS de Entre Douro e Vouga, EPE - Hospital de São Sebastião

🇵🇹

Santa Maria Da Feira, Aveiro, Portugal

ULS de Matosinhos, EPE - Hospital Pedro Hispano

🇵🇹

Senhora Da Hora, Porto, Portugal

Centro Clínico Académico, Braga - Hospital de Braga

🇵🇹

Braga, Portugal

ULS de Coimbra, EPE - Hospitais da Universidade de Coimbra

🇵🇹

Coimbra, Portugal

Hospital da Luz Torres de Lisboa

🇵🇹

Lisboa, Portugal

Hospital Universitario Germans Trias i Pujol

🇪🇸

Badalona, Barcelona, Spain

Hospital Universitario de Bellvitge

🇪🇸

L'Hospitalet De Llobregat, Barcelona, Spain

CHUVI - H.U. Alvaro Cunqueiro

🇪🇸

Vigo, Pontevedra, Spain

Hospital del Mar

🇪🇸

Barcelona, Spain

Hospital Regional Universitario de Malaga - Hospital General

🇪🇸

Málaga, Spain

Centro de Neurologia Avanzada

🇪🇸

Sevilla, Spain

Hospital Clinico Universitario de Valladolid

🇪🇸

Valladolid, Spain

© Copyright 2025. All Rights Reserved by MedPath